



IFW

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/782456
		Filing Date	February 19, 2004
		First Named Inventor	Patrick Andre
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	1	Attorney Docket Number	CFBF-P02-015

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please Identify below):
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	ROPES & GRAY LLP William G. Gosz - 27,787
Signature	
Date	June 22, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: <u>June 22, 2004</u>	Signature: (Patricia McKenney)



Application No.: 10/782456

Docket No.: CFBF-P02-015

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 6/22/04

Signature: 

(Patricia McKenney)

Docket No.: CFBF-P02-015
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Andre et al.

Application No.: 10/782456

Confirmation No.: @@@

Filed: February 19, 2004

Art Unit: N/A

For: METHODS FOR DIAGNOSING AND
TREATING HEMOSTATIC DISORDERS BY
MODULATING P-SELECTIN ACTIVITY

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 was cited in the parent US patent application No. 09/860,618 filed May 17, 2001.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this

Application No.: 10/782456

Docket No.: CFBF-P02-015

application by this firm) to our Deposit Account No. 18-1945, under Order No. CFBF-P02-015.

A duplicate copy of this paper is enclosed.

Dated: June 22, 2004

Respectfully submitted,

By William Gosz

William G. Gosz

Registration No.: 27,787

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

In re Patent Application of:
Andre et al.

Application No.: 10/782456

Confirmation No.: @@@

Filed: February 19, 2004

Art Unit: N/A

Examiner: Not Yet Assigned

METHODS FOR DIAGNOSING AND TREATING
HEMOSTATIC DISORDERS BY MODULATING P-
SELECTIN ACTIVITY

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,622,701	4/97	Berg	424	153.1	
	A2	5,800,815	09/98	Chestnut et al.	424	153.1	
	A3	5,807,745	09/98	Furie et al.	435	375	
	A4	5,843,707	12/98	Larsen et al.	435	69.1	
	A5	6,033,667	03/00	Chesnut et al.	424	153.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A6	WO 93/06863 A1	04/93	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)


	A7	GenBank Acc. No. NM_003005 for Homo sapiens selectin P (granule membrane protein 140kD, antigen CD62) (SELP), mRNA
	A8	GenBank Acc. No. M25322 for Human granule membrane protein-140 mRNA, complete cds
	A9	GenBank Acc. No. NM_013114 for Rattus norvegicus Selectin, platelet (Selp), mRNA
	A10	GenBank Acc. No. L23088 for Rattus-norvegicus-P-selectin-mRNA, complete cds
	A11	GenBank Acc. No. NM_011347 for Mus musculus selectin, platelet (Selp), mRNA
	A12	GenBank Acc. No. M87861 for Mus musculus P-selectin protein mRNA, complete cds
	A13	GenBank Acc. No. L12041 for Bovine P-selectin mRNA, complete cds
	A14	Andre, P. et al., "Pro-coagulant state resulting from high levels of soluble P-selectin in blood," <i>Proc Natl Acad Sci USA</i> 97(25):13835-40 (2000)
	A15	Auchampach, J.A., et al., "Cloning, sequence comparison and in vivo expression of the gene encoding rat P-selectin" <i>Gene</i> 145 (2), 251-255 (1994)
	A16	Berger, G. et al., "P-Selectin and platelet clearance," <i>Blood</i> 92(11):4446-52 (1998)
	A17	Bevilacqua, M., et al., "Selectins: a family of adhesion receptors," <i>Cell</i> 67 (2), 233 (1991)
	A18	Borsig, L. et al., "Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis," <i>Proc Natl Acad Sci USA</i> 98(6):3352-7 (2001)
	A19	Blann, A.D. et al., "Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers," <i>Thromb. Haemost.</i> 77(6):1077-80 (1997)
	A20	Celi, et al., "P-selectin induces the expression of tissue factor on monocytes," <i>Proc Natl Acad Sci USA</i> 91(19):8767-71 (1994)

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



In re Patent Application of:
Andre et al.

Application No.: 10/782456

Confirmation No.: @@@

Filed: February 19, 2004

Art Unit: N/A

For: METHODS FOR DIAGNOSING AND TREATING
HEMOSTATIC DISORDERS BY MODULATING P-
SELECTIN ACTIVITY

Examiner: Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

B1	Ertleni, I. et al., "P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis," <i>J. Rheumatol.</i> 25(6):1054-8 (1998)
B2	Ferroni, P. et al., "Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease," <i>J. Investig. Med.</i> 48(1):21-7 (2000)
B3	Gurbel, P.A. et al., "Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department," <i>Am. Heart J.</i> 139(2 Pt 1):320-8 (2000)
B4	Hartwell, D.W. et al., "Role of P-selectin cytoplasmic domain in granular targeting in vivo and in early inflammatory responses," <i>J. Cell Biol.</i> 143(4):1129-41 (1998)
B5	Haznedaroglu, I.C. et al., "Selectins and IL-6 during the clinical course of idiopathic thrombocytopenic purpura," <i>Acta Haematol.</i> 101(1):16-20 (1999)
B6	Inoue, T. et al., "Serum levels of circulating adhesion molecules after coronary angioplasty," <i>Cardiology</i> , 1999;91(4):236-42 (1999)
B7	Ishiwata, N. et al., "Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule," <i>J. Biol. Chem.</i> 269(38):23708-15 (1994)
B8	Johnston, G.I., et al., "Cloning of GMP-140, a granule membrane protein of platelets and endothelium: Sequence similarity to proteins involved in cell adhesion and inflammation," <i>Cell</i> 56, 1033-1044 (1989)
B9	Johnston, G.I., et al., "Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes," <i>J. Biol. Chem.</i> 265 (34), 21381-21385 (1990)
B10	Kopp, H.P. et al., "Concentrations of circulating P-selectin are increased in patients with newly diagnosed insulin-dependent diabetes mellitus," <i>Exp. Clin. Endocrinol. Diabetes</i> 106(1):41-4 (1998)
B11	Palabrica, T. et al., "Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets," <i>Nature</i> 359(6398):848-51 (1992)
B12	Pan, J. et al., "Characterization of the promoter for the human P-selectin gene," <i>J. Biol. Chem.</i> 268 (30), 22600-22608 (1993)
B13	Ridker, P.M. et al., "Soluble P-selectin and the risk of future cardiovascular events," <i>Circulation</i> 103:491-5 (2001)

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

C1	Ryan, U.S. et al., "Cell-cell contact mechanisms," <i>Curr. Opin. Immunol.</i> 4 (1), 33-37 (1992)
C2	Sanders, W.E. et al., "Molecular cloning and analysis of in vivo expression of murine P-selectin," <i>Blood</i> 80(3):795-800 (1992)
C3	Smith, A. et al., "Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis," <i>Thromb. Haemost.</i> 82(6):1593-9 (1999)
C4	Strubel, N.A., et al., "Isolation and characterization of a bovine cDNA encoding a functional homolog of human P-selectin," <i>Biochem. Biophys. Res. Commun.</i> 192, 338-344 (1993)
C5	Weller, A., et al., "Cloning of the mouse endothelial selectins: Expression of both E- and P-selectin is inducible by tumor necrosis factor alpha," <i>J. Biol. Chem.</i> 267, 15176-15183 (1992)
C6	Xu, D. et al., "Elevated plasma levels of soluble P-selectin in patients with acute myocardial infarction and unstable angina. An inverse link to lipoprotein(a)," <i>Int. J. Cardiol.</i> 64(3):253-8 (1998)
Examiner	Date Considered
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered: Include copy of this form with next communication to applicant.</p>	